Researchers characterized immunological responses by pulmonary mucosal tissues post-COVID-19 vaccination and/or SARS-CoV-2 infection, to assess the impact of hybrid immune protection on the durability of mucosal immunological responses.
In a recent study posted to the medRxiv* preprint server, researchers assessed immune responses to homologous and heterologous coronavirus disease 2019 (COVID-19) vaccine combinations among Córdoba, Spain residents.
Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.
Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.